Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing